Peter Thompson, Trubion Pharmaceuticals' president, CEO, chairman of the board and co-founder, has retired. Steven Gillis, former lead director of Trubion's board, has been appointed executive chairman of the board and acting president. Michelle Burris, Trubion's senior vice president and chief financial officer, will assume the role of chief operating officer, and John Bencich, the company's senior director of finance and accounting, has been promoted to vice president and chief financial officer.
Mirna Therapeutics names Paul Lammers as its president and CEO.
Cannasat Therapeutics appoints Anthony Giovinazzo to be company CEO.
Bruce Galton resigns as Senesco Techonolgies' president and CEO; Jack Van Hulst tapped as his replacement.
Steven Paul, executive vice president, science and technology, and president of Lilly Research Laboratories, will retire from Eli Lilly in February; Jan Lundberg, AstraZeneca's executive vice president and head of global discovery research, will succeed him.
Watson Pharmaceuticals has announced that Robert Stewart has joined the company in the newly created position of senior VP, global operations, effective immediately. Thomas Russillo, executive VP and president of the generics division, has been named executive VP, global generics.
Oxford BioTherapeutics expands U.S. operations, names Jim Cornett chief operating officer and Jon Terrett VP of Oncology.
CellCyte Genetics announces the appointment of Douglas Cerretti as chief science officer and director of business development.
XOMA has announced that James Neal has joined the company as VP of business development.
AnaptysBio has announced the appointment of Sean Stevens as director of cell biology.
Cornerstone Therapeutics names Andrew Powell general counsel.
Fred Hassan, who headed Schering-Plough until its recent merger with Merck, has been named to Bausch & Lomb's board.
Craig Mendelsohn joins Cytomedix's board of directors.
Caleco Pharma appoints Jim Metropoulos to advisory board.
Jaye Thompson named to Repros Therapeutics to board of directors.